Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors

Human Vaccines

Volumn 5, Issue 4, 2009, Pages 214-229

  Anton, Benito ^a   Salazar, Alberto ^a   Flores, Anabel ^a   Matus, Maura ^a   Marin, Rodrigo ^a   Hernandez, Jorge Alberto ^b   Leff, Philippe ^a  

^a INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^b Laboratories of Biologicals and Reagents of Mexico (BIRMEX)   (Mexico)

Author keywords

Active immunization; Addiction; Antibodies; Behavior; Immunogen; Immunoprotection; Neutralization; Opiates; Prevention; Relapse

Indexed keywords

3 CARBOXYMETHYL MORPHINE VACCINE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BENZODIAZEPINE DERIVATIVE; BOVINE SERUM ALBUMIN; BUPRENORPHINE; CLONIDINE; CODEINE; DIAMORPHINE; FENTANYL; GUANFACINE; KEYHOLE LIMPET HEMOCYANIN; LOFEXIDINE; M TT VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHADONE; MORPHINE; MORPHINE 6 HEMISUCCINYL VACCINE; MORPHINE 6 SUCCINYL VACCINE; NALOXONE; NALTREXONE; NEUROLEPTIC AGENT; OPIATE; PENTAZOCINE; PETHIDINE; THEBAINE; UNCLASSIFIED DRUG; VACCINE;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ANALGESIA; ANXIETY DISORDER; ASTHENIA; CLINICAL TRIAL; COGNITIVE DEFECT; DETOXIFICATION; DRUG ABSORPTION; DRUG ABUSE; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG FORMULATION; DRUG INTOXICATION; DRUG POTENCY; DRUG STRUCTURE; DYSPHORIA; EMOTIONAL DISORDER; HEROIN DEPENDENCE; HUMAN; HUMORAL IMMUNITY; HYPOTENSION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; INSOMNIA; IRRITABILITY; LD 50; MORPHINE ADDICTION; MUSCLE CRAMP; NAUSEA; NOCICEPTION; NONHUMAN; OPIATE ADDICTION; PREVALENCE; RESTLESSNESS; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINE PRODUCTION; WITHDRAWAL SYNDROME;

ANIMALS; ANTIBODIES; HEROIN; HEROIN DEPENDENCE; HUMANS; MORPHINE; MORPHINE DEPENDENCE; RATS; RECURRENCE; VACCINES, CONJUGATE;

EID: 70349504135     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.4.7556     Document Type: Review

References (152)

1. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry 2005; 162:1414-22.
2. Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 2001; 58:503-8.
3. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance and outcomes evaluation. JAMA 2000; 284:1689-95.
4. Kendler KS, Prescott CA, Myers J, Neale MC. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch Gen Psychiatry 2003; 60:929-37.
5. Rhee SH, Hewitt JK, Young SE, Corley RP, Crowley TJ, Stallings MC. Genetic and environmental influences on substance initiation, use and problem use in adolescents. Arch Gen Psychiatry 2003; 60:1256-64.
6. Merikangas KR, Stolar M, Stevens DE, Goulet J, Preisig MA, Fenton B, et al. Familial transmission of substance use disorders. Arch Gen Psychiatry 1998; 55:973-9.
7. Kalivas PW, Volkow ND. The neural basis of addiction: A pathology of motivation and choice. Am J Psychiatry 2005; 162:1403-13.
8. O'Brien CP, Childress AR, Ehrman R, Robbins SJ. Conditioning factors in drug abuse: can they explain compulsion? J Psychopharmacol 1998; 12:15-22.
9. Wikler A, Pescor F. Classical conditioning of a morphine abstinence phenomenon, reinforcement of opioid-drinking behavior and "relapse" in morphine-addicted rats. Psychopharmacologia 1967; 10:255-84.
10. Wolf ME. Addiction: making the connection between behavioral changes and neuronal plasticity in specific pathways. Mol Interv 2002; 2:146-57.
11. Tomkins DM, Sellers EM. Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence. CMAJ 2001; 164:817-21.
12. Kelley AE, Berridge KC. The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 2002; 22:3306-11.
13. Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P, Robbins TW. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann N Y Acad Sci 1999; 877:412-38.
14. Cassell MD, Freedman LJ, Shi C. The intrinsic organization of the central extended amygdala. Ann N Y Acad Sci 1999; 877:217-41.
15. Koob GF. The role of the striatopallidal and extended amygdala systems in drug addiction. Ann N Y Acad Sci 1999; 877:445-60.
16. Aston-Jones G, Delfs JM, Druhan J, Zhu Y. The bed nucleus of the stria terminalis. A target site for noradrenergic actions in opiate withdrawal. Ann N Y Acad Sci 1999; 877:486-98.
17. Di Chiara G, Tanda G, Bassareo V, Pontieri F, Acquas E, Fenu S, et al. Drug addiction as a disorder of associative learning. Role of nucleus accumbens shell/extended amygdala dopamine. Ann N Y Acad Sci 1999; 877:461-85.
18. Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc Natl Acad Sci USA 1995; 92:12304-8.
19. Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR, et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 2006; 26:6583-8.
20. Shalev U, Grimm JW, Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev 2002; 54:1-42.
21. Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 2004; 47:3-13.
22. Nestler EJ. From neurobiology to treatment: progress against addiction. Nat Neurosci 2002; 5:1076-9.
23. Deslandes PN, Pache DM, Sewell RD. Drug dependence: neuropharmacology and management. J Pharm Pharmacol 2002; 54:885-95.
24. Sevarino KA, Oliveto A, Kosten TR. Neurobiological adaptations to psychostimulants and opiates as a basis of treatment development. Ann N Y Acad Sci 2000; 909:51-87.
25. Koob GF. Neurobiology of addiction. Toward the development of new therapies. Ann N Y Acad Sci 2000; 909:170-85.
26. Ghodse H. Drugs of abuse and dependence. In: Ghodse H, ed. Drugs and Addictive Behaviour, a guide to treatment, 3rd ed. UK, Cambridge University Press 2002; 95-105.
27. Fischer B, Oviedo-Joekes E, Blanken P, Haasen C, Rehm J, Schechter MT, et al. Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics. J Urban Health 2007; 84:552-62.
28. Hser Y, Hoffman V, Grella C, Anglin M. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 2001; 58:503-8.
29. Adlaf E, Begin P, Sawka E. Canadian Addiction Survey (CAS). A National Survey of Canadians, Use of Alcohol and Other Drugs: Prevalence of Use and Related Harms: A Detailed Report. Ottawa: Canadian Centre on Substance Abuse 2005.
30. EMCDDA. Annual Report 2006: The State of the Drugs Problem in Europe. Lisbon: European Monitoring Centre for Drugs and Drug Addiction 2006.
31. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2005. National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies, NSDUH series H-30, DHHS Publication No. SMA 06-4194; 2006.
32. Healey A, Knapp M, Marsden J, Gossop M, Stewart D. Criminal outcomes and costs of treatment services for injecting and non-injecting heroin users: evidence from a national prospective cohort survey. J Health Serv Res Policy 2003; 8:134-41.
33. O' Brien CP. Drug Abuse, In: Hardman JG, Limbird LE, eds. The Pharmacological Basis of Therapeutics. New York NY. McGraw Hill 2001; 621-42.
34. The Office of National Drug Control Policy (ONDCP). Heroin Fact Sheet: June 2003.
35. Wiessing L, Roy K, Sapinho D, et al. Surveillance of Hepatitis C Infection Among Injecting Drug Users in the European Union. In: Jager J, Limburg W, Kretzschmar M, Postma M, Wiessing L, eds. EMCDDA Monographs: Hepatitis C and Injection Drug Use: Impact, Costs and Policy Options. Lisbon: European Monitoring Centre for Drugs and Drug Addiction 2004; 91-135.
36. Rehm J, Fischer B, Haydon E. Reducing the Risks, Harms and Costs of HIV/ AIDS and Injection Drug Use: A Synthesis of the Evidence Base for Development of Policies and Programs. Background Paper # 4. 2nd Annual Background Dialogue on HIV/AIDS. Warsaw: Health Canada/UNAIDS/Canadian International Development Agency 2003.
37. Darke S, Hall W. Heroin overdose: research and evidence-based intervention. J Urban Health 2003; 80:189-200.
38. Wodak A. The current status of heroin prescription treatment for heroin dependence. Expert Opin Drug Saf 2005; 4:815-9.
39. Mark T, Woody G, Juday T, Kleber H. The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001; 61:195-206.
40. The Senlis Council. Licensing poppy for the production of essential medicines: an integrated counter-narcotics, development and counter-insurgency model for Afghanistan. June 2007.
41. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2005; Volume I. Analysis.
42. International Narcotics Control Board (INCB): Yellow List: List of Narcotic Drugs Under International Control. December 2004.
43. Klous MG, Van den Brink W, Van Ree JM, Beijnen JH. Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients. Drug Alcohol Depend 2005; 80:283-95.
44. Evans CJ, Keith DE Jr, Morrison H, Magendzo K, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science 1992; 258:1952-5.
45. Wang BJ, Imai Y, Epplert MC, Gregor P, Spivak EC, Uhl RU. μ-Opiate receptor: cDNA cloning and expression. Proc Natl Acad Sci USA 1993; 90:10230-4.
46. Knapp RJ, Malatynska E, Collins N, Fang L, Wang JY, Hruby VJ, et al. Molecular biology and pharmacology of cloned opioid receptors. FASEB J 1995; 9:516-25.
47. Kieffer BL. Opioids: first lessons from knockout mice. Trends Pharmacol Sci 1999; 20:19-26.
48. Mansour A, Fox CA, Burke S, Meng F, Thompson RC, Akil H, et al. Mu, delta and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol 1994; 350:412-38.
49. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Anatomy of CNS opioid receptors [review]. Trends Neurosci 1988; 11:308-14.
50. Messmer D, Hatsukari I, Hitosugi N, Schmidt-Wolf IG, Singhal PC. Morphine reciprocally regulates IL-10 and IL-12 production by monocyte-derived human dendritic cells and enhances T cell activation. Mol Med 2006; 12:284-90.
51. Zadina JE, Martin-Schild S, Gerall AA, Kastin AJ, Hackler L, Ge LJ, et al. Endomorphins: novel endogenous mu-opiate receptor agonists in regions of high mu-opiate receptor density. Ann N Y Acad Sci 1999; 897:136-44.
52. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996; 383:819-23.
53. Tschacher W, Haemmig R, Jacobshagen N. Time series modeling of heroin and morphine drug action. Psychopharmacology (Berl) 2003; 165:188-93.
54. Gutstein BH, Akil H. Opioid Analgesics, In: Hardman JG, Limbird LE, eds. The Pharmacological Basis of Therapeutics. New York NY. McGraw Hill 2001; 569-619.
55. O'Mahony S, Coyle N, Payne R. Current management of opioid-related side effects. Oncology 2001; 15:61-73.
56. Manzanares J, Corchero J, Romero J, Fernández-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999; 20:287-94.
57. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004; 11:354-65.
58. Weber RJ, Gomez-Flores R, Smith JE, Martin TJ. Immune, neuroendocrine and somatic alterations in animal models of human heroin abuse. J Neuroimmunol 2004; 147:134-7.
59. Ghodse AH, Reed JL. Gastric emptying, glucose tolerance and associated hormonal changes in heroin addiction. Psychol Med 1984; 14:521-5.
60. Inturrisi CE, Schultz M, Shin S, Umans JG, Angel L, Simon EJ. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci 1983; 33:773-6.
61. Inturrisi CE, Max MB, Foley KM, Schultz M, Shin SU, Houde RW. The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med 1984; 310:1213-7.
62. Kamendulis LM, Brzezinski MR, Pindel EV, Bosron WF, Dean RA. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J Pharmacol Exp Ther 1996; 279:713-7.
63. Glare PA, Walsh TD. Clinical pharmacokinetics of morphine. Ther Drug Monit 1991; 13:1-23.
64. Milne RW, Nation RL, Somogyi AA. The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev 1996; 28:345-472.
65. Sawynok J. The therapeutic use of heroin: a review of the pharmacological literature. Canadian Journal of Physiology and Pharmacology 1986; 64:1-6.
66. Shigeev S. Severity of opiate intoxication to gender and age. Soud Lek 2007; 52:21-4.
67. Martin WR, Fraser HF. A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in postaddicts. J Pharmacol Exp Ther 1961; 133:388-99.
68. Hutto CW Jr, Crowder WF. Dosage choices of rats for morphine, for heroin and between morphine and heroin. Pharmacol Biochem Behav 1997; 58:133-40.
69. Grilly DM. Opioids (narcotics) and their antagonists. In: Allyn and Bacon, eds. Drugs and human behaviour, 4th ed. Boston MA. Oxford University Press 2002; 238-62.
70. Kaur AD, McQueen A, Jan S. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use. J Manag Care Pharm 2008; 14:186-94.
71. Manchikanti L, Atluri S, Trescot A, Giordano J. Monitoring opioid adherence in chronic pain patients: Tools, techniques and utility. Pain Physician 2008; 11:155-80.
72. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci 2000; 909:186-216.
73. Shewan D, Dalgarno P. Evidence for controlled heroin use: high levels of negative health and social outcomes among non-treatment heroin users in Glasgow. Bri J Health Psychol 2005; 10:33-48.
74. Sterrett C, Brownfield J, Korn CS, Hollinger M, Henderson SO. Patterns of presentation in heroin overdose resulting in pulmonary edema. Am J Emerg Med 2004; 22:316.
75. Smith JE, Co C, Coller MD, Hemby SE, Martin TJ. Self-administered heroin and cocaine combinations in the rat: additive reinforcing effects-supra-additive effects on nucleus accumbens extracellular dopamine. Neuropsychopharmacology 2006; 31:39-50.
76. Hill MD, Cooper PW, Perry JR. Chasing the dragon. Neurological toxicity associated with inhalation of heroin vapour: case report. CMAJ 2000; 162:236-8.
77. Sporer KA. Acute heroin overdose. Ann Intern Med 1999; 130:584-90.
78. Michelson JB, Robin HS, Nozik RA. Nonocular manifestations of parenteral drug abuse. Surv Ophthalmol 1986; 30:314-20.
79. Jaffe JA, Kimmel PL. Chronic nephropathies of cocaine and heroin abuse: a critical review. Clin J Am Soc Nephrol 2006; 1:655-67.
80. Abbas AK, Lichtman A, Pillai S. The immune system in defense and disease. In: Abbas Ak, Lichtman A and Pillai S, eds. Cellular and Molecular Immunology. 6th ed. Philadelphia PA, USA: Saunders Elsevier 2007; 351-73.
81. Cerny EH, Cerny T. Anti-nicotine abuse vaccines in the pipeline: an update. Expert Opin Investig Drugs 2008; 17:691-6.
82. Maurer P, Bachmann MF. Therapeutic vaccines for nicotine dependence. Curr Opin Mol Ther 2006; 8:11-6.
83. Anton B, Leff P. A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 2006; 24:3232-40.
84. Meijler MM, Matsushita M, Wirsching P, Janda KD. Development of immunopharmacotherapy against drugs of abuse. Curr Drug Discov Technol 2004; 1:77-89.
85. Haney M, Kosten TR. Therapeutic vaccines for substance dependence. Expert Rev Vaccines 2004; 3:11-8.
86. Kosten TR, Biegel D. Therapeutic vaccines for substance dependence. Expert Rev Vaccines 2002; 1:363-71.
87. Bunce CJ, Loudon PT, Akers C, Dobson J, Wood DM. Development of vaccines to help treat drug dependence. Curr Opin Mol Ther 2003; 5:58-63.
88. Kantak KM. Anti-cocaine vaccines: antibody protection against relapse. Expert Opin Pharmacother 2003; 4:213-8.
89. Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ, et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996; 2:1129-32.
90. Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000; 65:191-8.
91. Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 1974; 252:708-10.
92. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci 2005; 8:1445-9.
93. Abbas AK, Lichtman A, Pillai S. B cell activation and antibody production. In: Abbas Ak, Lichtman A and Pillai S, eds. Cellular and Molecular Immunology. 6th ed. Philadelphia PA, USA: Saunders Elsevier 2007; 215-41.
94. Wainer BH, Fitch FW, Rothberg RM, Fried J. Morphine-3-succinyl - bovine serum albumin: an immunogenic hapten-protein conjugate. Science 1972; 176:1143-5.
95. Wainer BH, Fitch FW, Fried J, Rothberg RM. A measurement of the specificities of antibodies to morphine-6-succinyl-BSA by competitive inhibition of 14 C-morphine binding. J Immunol 1973; 110:667-73.
96. Wainer BH, Fitch FW, Rothberg RM, Schuster CR. In vitro morphine antagonism by antibodies. Nature 1973; 241:537-8.
97. Akbarzadeh A, Mehraby M, Zarbakhsh M, Farzaneh H. Design and synthesis of a morphine-6-succinyl-bovine serum albumin hapten for vaccine development. Biotechnol Appl Biochem 1999; 30:139-46.
98. Van Regenmortel MH. From absolute to exquisite specificity. Reflections on the fuzzy nature of species, specificity and antigenic sites. J Immunol Meth 1998; 216:37-48.
99. Van Regenmortel MH. Antigenicity and inmunogenicity of synthetic peptides. Biologicals 2001; 29:209-13.
100. Berzofsky AJ, Berkahuer JI. In: Paul EW, ed. Regulation of immune response: immunogenicity and antigen structure. Philadelphia PA, 5th ed; Lippincott, Williams and Wilkins Inc 2003; 631-84.
101. Spector S, Parker CW. Morphine: radioimmunoassay. Science 1970; 168:1347-8.
102. Spector S. Quantitative determination of morphine in serum by radioimmunoassay. J Pharmacol Exp Ther 1971; 178:253-8.
103. Adler FL, Liu CT. Detection of morphine by hemagglutination-inhibition. J Immunol 1971; 106:1684-5.
104. Van Vunakis H, Wasserman E, Levine L. Specificities of antibodies to morphine. J Pharmacol Exp Ther 1972; 180:514-21.
105. Hill JH, Wainer BH, Fitch FW, Rothberg RM. Delayed clearance of morphine from the circulation of rabbits immunized with morphine-6-hemisuccinate bovine serum albumin. J Immunol 1975; 114:1363-8.
106. Cerny EH. Vaccine and immunoserum against drug of abuse. Patent registries # WO 92/03163 and PCT/CH91/00016, 1992; 1-17.
107. Wainer BH, Fitch FW, Rothberg RM, Fried J. The structure of morphine monohemisuccinate. Science 1972; 178:647-8.
108. Liu LI, Ping Z, Jian-Ping XU, Ning FU. Preparation of anti-morphine monoclonal antibodies with complete cross reactivity with heroin. J First Mil Med Univ 2005; 25:833-6.
109. Anton B, Leff P. Addictive morphine and heroin self-administration behavior is prevented after active immunization with a morphine vaccine in the rodent. Program No. 685.7, 2001 Abstract Viewer/Itinerary Planner. San Diego, CA: Society for Neuroscience 2001; Online.
110. Dennehy PH. Active immunization in the United States: developments over the past decade. Clin Microbial Rev 2001; 14:872-908.
111. Gross SJ, Grant JD, Wong SR, Schuster R. Critical antigenic determinants for production of antibody to distinguish morphine from heroin, codeine and dextromethorphan. Immunochemistry 1974; 11:453-6.
112. Sawada JI, Yamazaki T, Terao T. Molecular and biochemical analyses of combining sites of monoclonal anti-morphine antibodies. Mol Immunol 1992; 30:77-86.
113. Boerner U. The metabolism of morphine and heroin in man. Drug Metab Rev 1975; 4:39-73.
114. Carrupt PA, Testa B, Bechalany A, el Tayar N, Descas P, Perrissoud D. Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. J Med Chem 1991; 34:1272-5.
115. Salem A, Hope W. Role of morphine glucuronide metabolites in morphine dependence in the rat. Pharmacol Biochem Behav 1997; 57:801-7.
116. Abbott FV, Palmour RM. Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats. Life Sci 1988; 43:1685-95.
117. Aderjan RE, Skopp G. Formation and clearance of active and inactive metabolites of opiates in humans. Ther Drug Monit 1998; 20:561-9.
118. Parkinson A. Biotransformation of Xenobiotics, In: Klaassen DC, Amdur OM, Doull J, eds. Casarett & Doull's Toxicology: The Basic Science of Poisons. New York, McGraw Hill 1996; 113-86.
119. Christrup LL. Morphine metabolites. Acta Anaesthesiol Scand 1997; 41:116-22.
120. Coughtrie MW, Ask B, Rane A, Burchell B, Hume R. The enantioselective glucuronidation of morphine in rats and humans. Evidence for the involvement of more than one UDP-glucuronosyltransferase isoenzyme. Biochem Pharmacol 1989; 38:3273-80.
121. Shimomura K, Kamata O, Ueki S, Ida S, Oguri K. Analgesic effect of morphine glucuronides. Tohoku J Exp Med 1971; 105:45-52.
122. Osborne R, Joel S, Slevin M. Morphine intoxication in renal failure; the role of morphine-6-glucuronide. Br Med J 1986; 293:1101
123. Osborne R, Thompson P, Joel S, Trew D, Patel N, Slevin M. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992; 34:130-8.
124. Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 1989; 251:477-83.
125. Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE. Morphine-6-glucuronide, a potent mu agonist. Life Sci 1987; 41:2845-9.
126. Mantione KJ, Goumon Y, Esch T, Stefano GB. Morphine 6beta glucuronide: fortuitous morphine metabolite or preferred peripheral regulatory opiate? Med Sci Monit 2005; 11:43-6.
127. Neumann PB, Henriksen H, Grosman N, Christensen CB. Plasma morphine concentrations during chronic oral administration in patients with cancer pain. Pain 1982; 13:247-52.
128. Sawe J. Morphine and its 3- and 6-glucuronides in plasma and urine during chronic oral administration in cancer patients. In: Foley KM, Intturrisi CE, eds. Advances in Pain Research and Therapy, vol. 8. New York. Raven Press 1986; 45-56.
129. Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48:2165-71.
130. Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide: A potent antagonist of morphine analgesia. Life Sci 1990; 47:579-85.
131. Gong QL, Hedner T, Hedner J, Björkman R, Nordberg G. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. Eur J Pharmacol 1991; 193:47-56.
132. Van Crugten JT, Somogyi AA, Nation RL, Reynolds G. Concentration-effect relationships of morphine and morphine-6 beta-glucuronide in the rat. Clin Exp Pharmacol Physiol 1997; 24:359-64.
133. Yoshimura H, Ida S, Oguri K, Tsukamoto H. Biochemical basis for analgesic activity of morphine-6-glucuronide I. Penetration of morphine-6-glucuronide in the brain of rats. Biochem Pharmacol 1973; 22:1423-30.
134. Smith ML, Shimomura ET, Summers J, Paul BD, Jenkins AJ, Darwin WD, et al. Urinary excretion profiles for total morphine, free morphine and 6-acetylmorphine following smoked and intravenous heroin. J Anal Toxicol 2001; 25:504-14.
135. Halliday AJ, Bartlett SE, Colditz P, Smith MT. Brain region-specific studies of the excitatory behavioral effects of morphine-3-glucuronide. Life Sci 1999; 65:225-36.
136. Selley DE, Cao CC, Sexton T, Schwegel JA, Martin TJ, Childers SR. mu Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. Biochem Pharmacol 2001; 62:447-55.
137. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81:429-44.
138. Romach MK, Otton SV, Somer G, Tyndale RF, Sellers EM. Cytochrome P450 2D6 and treatment of codeine dependence. J Clin Psychopharmacol 2000; 20:43-5.
139. Osborne PB, Chieng B, Christie MJ. Morphine-6 beta-glucuronide has a higher efficacy than morphine as a mu-opioid receptor agonist in the rat locus coeruleus. Br J Pharmacol 2000; 131:1422-8.
140. Volkow ND, Li TK. Drug addiction: the neurobiology of behaviour gone awry. Nat Rev Neurosci 2004; 5:963-70.
141. Nestler EJ. Molecular mechanisms of drug addiction. Neuropharmacology 2004; 47:24-32.
142. Robbins TW, Everitt BJ. Drug addiction: bad habits add up. Nature 1999; 398:567-70.
143. Leshner AI. Addiction is a brain disease, and it matters. Science 1997; 278:45-7.
144. Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science 1997; 278:58-63.
145. Schindler CW, Panlilio LV, Goldberg SR. Second-order schedules of drug self-administration in animals. Psychopharmacology (Berl) 2002; 163:327-44.
146. Alderson HL, Robbins TW, Everitt BJ. Heroin self-administration under a second-order schedule of reinforcement: acquisition and maintenance of heroin-seeking behaviour in rats. Psychopharmacology (Berl) 2000; 153:120-33.
147. Mierzejewski P, Koros E, Goldberg SR, Kostowski W, Stefanski R. Intravenous self-administration of morphine and cocaine: a comparative study. Pol J Pharmacol 2003; 55:713-26.
148. Leri F, Tremblay A, Sorge RE, Stewart J. Methadone maintenance reduces heroin- and cocaine-induced relapse without affecting stress-induced relapse in a rodent model of poly-drug use. Neuropsychopharmacology 2004; 29:1312-20.
149. Sorge RE, Stewart J. The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration. Psychopharmacology (Berl) 2006; 188:28-41.
150. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005; 58:158-64.
151. LeSage MG, Keyler DE, Pentel PR. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. AAPS J 2006; 8:65-75.
152. Gamaleya N, Tagliaro F, Parshin A, Vrublevski A, Bugari G, Dorizzi R, et al. Immune response to opiates: new findings in heroin addicts investigated by means of an original enzyme immunoassay and morphine determination in hair. Life Sci 1993; 53:99-105.